Jobs
-
Nocion Therapeutics, which is developing inhaled dry powder taplucainium (NOC-110, formerly NTX-1175) for the treatment of chronic cough, has announced the appointment of Matthew Frankel as Chief Medical Officer. Frankel was most recently Chief Medical… Read more . . .
-
Akita Biosciences announced that a grant from Flu Lab will fund a pilot study of the company’s Profi prophylactic nasal spray in healthcare workers. Akita launched Profi, an OTC gel-forming drug-free nasal spray, in 2023… Read more . . .
-
Swedish DPI developer Iconovo has announced that it will lay off about 10 employees as it switches its focus to commercialization of its existing dry powder inhalation platforms, including the ICOres reservoir-based DPI, the ICOpre… Read more . . .
-
Rein Therapeutics says that the US Patent and Trademark Office (USPTO) has recently granted US Patents No. 12,280,088 and No. 12,280,089, which cover the dry powder peptide formulation of the company’s lead candidate, LTI-03. Both of the new… Read more . . .
-
CDMO Kindeva has announced the appointment of Melanie Cerullo as Chief Quality Officer. Cerullo was most recently Chief Quality and Regulatory Officer at Recipharm’s ReciBioPharm business unit and previously served in quality roles at Wave Life… Read more . . .
-
AptarGroup announced that its subsidiary Nanopharm is initiating a clinical study to validate the SmartTrack in-vitro-in-silico modeling platform as an alternative to clinical endpoint studies for determining bioequivalence of inhaled drug products. The study will… Read more . . .
-
Neurelis announced that the FDA has approved the use of Valtoco diazepam nasal spray for the treatment of seizure clusters in children aged 2 years of age and older. The FDA approved Valtoco for use in… Read more . . .
-
Aurobindo has reported to the National Stock Exchange of India that the FDA issued a Form 483 on April 11, 2025, one day after the agency completed an inspection of a manufacturing facility in North… Read more . . .
-
German biotech startup AATec Medical announced that it has raised €4 million prior to a series A financing, with the funds going to development of the company’s ATL-105 inhaled recombinant alpha-1 antitrypsin (AAT) for the… Read more . . .
-
According to Orexo, a dry powder formulation of an intranasal influenza vaccine formulated with the company’s AmorphOX powder engineering platform has produced a similar immune response in rats compared to a liquid formulation of the… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
July 13-July 16: 2026 ISAM Congress, Taipei, Taiwan
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA